期刊文献+

阿扎那韦质量标准概述 被引量:2

Review on Atazanavir Quality Standards
暂未订购
导出
摘要 目的讨论用于HIV-1感染治疗药物——阿扎那韦的质量控制关键属性。方法从阿扎那韦制备工艺入手,对其各个环节可能引入的杂质进行分析。结果与结论确定在生产工艺过程中可能引入的杂质以及成品中可能残存的有机溶剂,从而得出阿扎那韦质量标准中所需控制的关键点。 Objective To determine the key attributes of atazanavir quality control, which is used for treating HIV-1. Methods Based on the preparation process of atazanavir, possible impurities introduced during the production procedures were analyzed. Results and Conclusion Impurities and remaining organic solvents were determined, from which the key attributes in atazanavir quality standards were drawn.
作者 汪麟
出处 《中国药事》 CAS 2014年第4期413-417,共5页 Chinese Pharmaceutical Affairs
关键词 阿扎那韦 质量标准 生产工艺 atazanavir quality standard production process
  • 相关文献

参考文献11

  • 1Massimiliano Fabbiani, Laura Bracciale, Maria Doino, et al. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients [J]. Journal of Infection, 2011, 62 (4): 319-322.
  • 2Croom KF, Dhillon S, Keam SJ. Atazanavir [J]. Drugs, 2009, 69 (8): 1107-1140.
  • 3Ly T, Ruiz M. Prolonged QT interval and torsades de pointes associated with atazanavir therapy [J]. Clin Infect Dis, 2007, 44 (6): 67-68.
  • 4陈依军,吴旭日.生物催化与新药研究和开发[J].化学进展,2007,19(12):1947-1954. 被引量:5
  • 5倪倩,凌飒,陈本川.新型HIV蛋白酶抑制剂阿扎那韦[J].世界临床药物,2005,26(11):686-690. 被引量:2
  • 6牟英迪,林振广,刘宜辉.抗HIV病毒感染新药——硫酸阿扎那韦[J].齐鲁药事,2007,26(4):253-253. 被引量:3
  • 7Pyrko P, Kardosh A, Wang W, et al. HIV-1 protease in hibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmie retieulum stress [J]. Cancer Research, 2006, 67 (22): 92-97.
  • 8G Bold, A Fassler, H G Capraro, et al. New aza-dipeptide analogues as potent and orally absorbed HIV 1 protease inhibitors: candidates for clinical development [J]. Researchgate, 1998, 41 (18): 387-401.
  • 9K SRINIVASU. A Validated RP-HPLC Method for the Determination of Atazanavir in Pharmaceutical Dosage Form [J]. E-Journal of Chemistry, 2011, 8 (1): 453-456.
  • 10Suddhasattya Dey. Method Development and Validation for the Estimation of Atazanavir in Bulk and Pharmaceutical Dosage Forms and Its Stress Degradation Studies Using UV Vis Spectrophotometric Method [J]. International Journal of Pharma and Bio Sciences, 2010, 1 (3) :403-414.

二级参考文献39

  • 1Rozzell D J. Bioorg. Med. Chem., 1999, 7(10) : 2253-2261
  • 2Wandrey C, Liese A, Kihumbu D. Org. Process Res. Dev., 2000, 4(4) : 286-290
  • 3Straathof A J, Panke A, Schmid A. Curr. Opin. Biotech., 2002, 13:548-556
  • 4Johannes T, Simurdiak M R, Zhao H. Encyclopedia of Chemical Processing, 2006, 10:101-110
  • 5Faber K. Biotransformation in Organic Chemistry, 4th ed. Germany: Springer-Verlag, 1999. 8-9
  • 6Michels P C, Khmelnltsky Y L, Dordick J S, et al. Trends Biotechnol., 1998, 16(5): 210-215
  • 7Mozhaev V V, Budde C L, Rich J O, et al. Tetrahedron, 1998, 54(16) : 3971-3982
  • 8De la Goutte J T, Khan A J, Vulfson E N. Biotechnol. Bioeng., 2001, 75(1) : 93-99
  • 9Fura A, Shu Y Z, Zhu M, et al. J. Med. Chem., 2004, 47 (18) : 4340- 4351
  • 10Norman P, Dihlmann A, Rabasseda X. Drugs Today, 2001, 37 (4) : 215-227

共引文献7

同被引文献5

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部